|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
19
|
|
pubmed:dateCreated |
1999-2-2
|
|
pubmed:abstractText |
A series of novel 2-pyridinyl-3-(4-methylsulfonyl)phenylpyridines has been synthesized and evaluated with respect to their ability to inhibit the isozymes of cyclooxygenase, COX-1, and COX-2. Optimum COX-2 activity is observed by introduction of a substituent at C5 of the central pyridine. 5- Chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine 33 was identified as the optimum compound in this series.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 1,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2 Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/PTGS1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/PTGS2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin-Endoperoxide Synthases,
http://linkedlifedata.com/resource/pubmed/chemical/Ptgs1 protein, rat,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:BrideauCC,
pubmed-author:ChanC CCC,
pubmed-author:CharlesonSS,
pubmed-author:DeschênesDD,
pubmed-author:DubéDD,
pubmed-author:EthierDD,
pubmed-author:FortinRR,
pubmed-author:FriesenR WRW,
pubmed-author:GauthierJ YJY,
pubmed-author:GirardYY,
pubmed-author:GordonRR,
pubmed-author:GreigG MGM,
pubmed-author:RiendeauDD,
pubmed-author:SavoieCC,
pubmed-author:ViscoDD,
pubmed-author:WangZZ,
pubmed-author:WongEE,
pubmed-author:YUL KLK,
pubmed-author:YoungR NRN
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
6
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2777-82
|
|
pubmed:dateRevised |
2005-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9873621-Administration, Oral,
pubmed-meshheading:9873621-Animals,
pubmed-meshheading:9873621-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:9873621-CHO Cells,
pubmed-meshheading:9873621-Cricetinae,
pubmed-meshheading:9873621-Cyclooxygenase 1,
pubmed-meshheading:9873621-Cyclooxygenase 2,
pubmed-meshheading:9873621-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:9873621-Cyclooxygenase Inhibitors,
pubmed-meshheading:9873621-Edema,
pubmed-meshheading:9873621-Humans,
pubmed-meshheading:9873621-Isoenzymes,
pubmed-meshheading:9873621-Membrane Proteins,
pubmed-meshheading:9873621-Prostaglandin-Endoperoxide Synthases,
pubmed-meshheading:9873621-Pyridines,
pubmed-meshheading:9873621-Rats,
pubmed-meshheading:9873621-Structure-Activity Relationship
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.
|
|
pubmed:affiliation |
Merck Frosst Centre for Therapeutic Research, Pointe Claire-Dorval, Québec, Canada.
|
|
pubmed:publicationType |
Journal Article
|
